Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report

BACKGROUND: Immune checkpoint inhibitor (ICPi) has become a major treatment in advanced non-small cell lung cancer (NSCLC) and demonstrated a clinical benefit for NSCLC patients with high programmed death ligand-1 (PD-L1) expression without EGFR/ALK/ROS1 drivers; however, the benefit in BRAF V600E N...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Xiaomin, Sun, Yingjia, Planchard, David, Chiu, Luting, Bai, Jian, Ai, Xinghao, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222507/
https://www.ncbi.nlm.nih.gov/pubmed/34178624
http://dx.doi.org/10.3389/fonc.2021.634920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222507/
https://www.ncbi.nlm.nih.gov/pubmed/34178624
http://dx.doi.org/10.3389/fonc.2021.634920

Ejemplares similares